Top

Published in:

01-09-2015 | Letter

Management of nicotinamide N-methyltransferase overexpression: inhibit the enzyme or reduce nicotinamide intake? Reply to Zhou S, Li D, Zhou Y [letter]

Authors: Aimo Kannt, Anja Pfenninger, Anke Tönjes, Matthias Blüher

Published in: Diabetologia | Issue 9/2015

Excerpt

To the Editor: In their letter to Diabetologia [1], Zhou and colleagues suggest that inhibition of nicotinamide N-methyltransferase (NNMT) may not be a viable therapeutic approach for insulin resistance or type 2 diabetes. Instead, the authors propose to reduce nicotinamide intake or increase its elimination, implicating that it is the excess nicotinamide that is causative in the development of metabolic diseases. They postulate that our finding of higher adipose tissue NNMT expression and plasma 1-methylnicotinamide (MNA) levels in patients with insulin resistance and type 2 diabetes [2] may be the result of an induction in NNMT expression by increased nicotinamide intake rather than the metabolic disease itself. …

Zhou SS, Li D, Zhou Y (2015) Management of nicotinamide N-methyltransferase overexpression: inhibit the enzyme or reduce nicotinamide intake? Diabetologia doi:10.1007/s00125-0151-3677-6

Kannt A, Pfenninger A, Teichert L et al (2015) Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistance. Diabetologia 58:799–808PubMedCentralPubMedCrossRef

Riederer M, Erwa W, Zimmermann R, Frank S, Zechner R (2009) Adipose tissue as a source of nicotinamide N-methyltransferase and homocysteine. Atherosclerosis 204:412–417PubMedCrossRef

Kraus D, Yang Q, Kong D et al (2014) Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature 508:258–264PubMedCentralPubMedCrossRef

Salek RM, Maguire ML, Bentley E et al (2007) A metabolomic comparison of urinary changes in type 2 diabetes in mouse, rat, and human. Physiol Genomics 29:99–108PubMedCrossRef

Li D, Tian YJ, Guo J, Sun WP et al (2013) Nicotinamide supplementation induces detrimental metabolic and epigenetic changes in developing rats. Br J Nutr 110:2156–2164PubMedCrossRef

Chang AM, Smith MJ, Galecki AT, Bloem CJ, Halter JB (2006) Impaired beta-cell function in human aging: response to nicotinic acid-induced insulin resistance. J Clin Endocrinol Metab 91:3303–3309PubMedCrossRef

Kahn SE, Beard JC, Schwartz MW et al (1989) Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes 38:562–568PubMedCrossRef

Greenbaum CJ, Kahn SE, Palmer JP (1996) Nicotinamide’s effects on glucose metabolism in subjects at risk for IDDM. Diabetes 45:1631–1634PubMedCrossRef

10.

Zhou SS, Li D, Zhou YM, Sun WP, Liu QG (2010) B-vitamin consumption and the prevalence of diabetes and obesity among the US adults: population based ecological study. BMC Public Health 10:746PubMedCentralPubMedCrossRef

11.

Zhou SS, Li D, Sun WP et al (2009) Nicotinamide overload may play a role in the development of type-2 diabetes. World J Gastroenterol 15:5674–5684PubMedCentralPubMedCrossRef

12.

Li D, Sun WP, Zhou YM et al (2010) Chronic niacin overload may be involved in the increased prevalence of obesity in US children. World J Gastroenterol 16:2378–2387PubMedCentralPubMedCrossRef

13.

Schmeisser K, Mansfeld J, Kuhlow D et al (2013) Role of sirtuins in lifespan regulation is linked to methylation of nicotinamide. Nat Chem Biol 9:693–700PubMedCentralPubMedCrossRef

14.

Ulanovskaya OA, Zuhl AM, Cravatt BF (2013) NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink. Nat Chem Biol 9:300–306PubMedCentralPubMedCrossRef

Title: Management of nicotinamide N-methyltransferase overexpression: inhibit the enzyme or reduce nicotinamide intake? Reply to Zhou S, Li D, Zhou Y [letter]
Authors: Aimo Kannt
Anja Pfenninger
Anke Tönjes
Matthias Blüher
Publication date: 01-09-2015
Publisher: Springer Berlin Heidelberg
Published in: Diabetologia / Issue 9/2015
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-015-3678-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 9/2015

Diagnosis of gestational diabetes, defining the net, refining the catch